🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

RecruitingPhase 2Ages 18 Years - anyAllInstitute of Hematology & Blood Diseases Hospital…
NCT05958719 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments. Younger patients (≤70) receive the full CAMP regimen, while older patients receive a modified version (CAMP-light). Patients are assessed via PET-CT after 4 cycles. Responders (CR/PR) receive consolidation therapy and then maintenance chidamide for 2 years. Eligible patients achieving CR after 4 cycles can get a transplant, while those with PR need 2 more cycles first. Patients with stable or progressive disease after 4 cycles are withdrawn. Progression at any time leads to study discontinuation.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Subjects must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma. 2. More than 18 years of age. 3. Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) platelet count (≥75×10\^9/L); 3) Serum total bilirubin ≤ 1.5 times ULN; 4) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 times ULN; 5) Serum creatinine (Cr) ≤2 ULN, or glomerular filtration rate ≥40ml/min; 4. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. 5. LVEF value measured by echocardiography ≥50%. 6. Life expectancy \> 3 months. Exclusion Criteria: 1. Patients who have previously received chemotherapy, radiotherapy or other antitumor therapy. 2. Patients with central nervous system involvement by lymphoma. 3. Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases. 4. Pregnant or breastfeeding women. 5. Presence of human immunodeficiency virus (HIV) virus infection. 6. Previous history of other malignant tumors, unless the disease has been cured for 5 years or more. The following cured tumors are excluded: 1. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin and related localized non-melanoma skin cancers; 2. Carcinoma in situ of the cervix
💊

What it tests

  • Chidamide
  • Azacitidine
  • liposomal mitoxantrone
  • prednisone
📍

Where

1 site
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy